IRVINE, Calif.--(BUSINESS WIRE)--IDM Pharma, Inc. (NASDAQ: IDMI) today announced that the Company will hold a conference call on Wednesday afternoon, May 9th to discuss the outcome of the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee meeting for Junovan™ (mifamurtide), the Company’s investigational immunotherapy for the treatment of newly diagnosed resectable high grade osteosarcoma following surgical resection in combination with multiple agent chemotherapy.
